Rallybio reports Q2 net loss $11.1M; IPO gross proceeds $92.7M; pipeline on track for Phase 1 starts in Q1 2022

Rallybio Corp

Net loss of $11.1M ($2.80 per common unit) for Q2 2021, vs $4.9M in Q2 2020.
Cash and investments $112.7M as of June 30; August IPO added ~$83.2M net proceeds.
R&D expenses $6.8M in Q2 2021, up from $3.1M YoY, driven by RLYB212 and RLYB116 development.
Phase 1/2 data for RLYB211 (FNAIT) presented at ISTH; additional data expected Q4 2021.
Phase 1 studies of RLYB212 and RLYB116 planned to initiate in Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.